Characteristics and survival rates of Acute Lymphoblastic Leukemia: A Retrospective cohort study

Authors

  • Samer Akel Tishreen University

Abstract

Background: Acute lymphoblastic leukemia (ALL) is the most common hematologic neoplasm in childhood, whereas it makes up for almost 20% of leukemias in adults. Despite the many reports about the outcomes and prognostic factors from developed countries; such reports are rare in the Middle East.

Methods: This is a retrospective study of newly diagnosed and previously untreated acute lymphoblastic leukemia patients who were admitted to the oncology department in Tishreen University Hospital in Latakia, Syria between 2007 and 2016. Patients of all ages were enrolled in the study. Patient data were collected, including: Age, gender, area of residence, laboratory results, existence of visceral or nodular enlargements on CT-scan, ALL subtype and CD10 expression. We listed which chemotherapeutic regimen was used. The initial response post-induction was documented based on minimal residual disease. Finally, survival rates were calculated after 5 years of diagnosis. The ending point was confirmed death.

Results: This study included 129 patients. The number of males was 82. Complete remission after the first induction was achieved in 66 patients (51.2%), and 54 patients died during the five year observation period. B-lineage ALL was predominant, with pre-B-ALL being the most common subtype (27.9%). The best survival rates were seen in ages 1 to 13. There rates dropped gradually with age. A WBC count higher than 50 10*3/µL was associated with lower survival rates. Pre-B and common B subtypes had the highest survival rates, while cortical and pre-T subtype leukemias had the worst. Patients with a positive CD10 expression had better survival rates. Finally, achieving complete remission after the first induction had a statistical; but not a clinical prognostic value. Other variables such as gender, HGB, PLT, radiographic findings and regimens didn’t have any effect on survival.

Conclusion: Age, WBC count at diagnosis, ALL subtype, CD10 expression and achieving complete remission after the first induction are all considered prognostic factors in acute lymphoblastic leukemia patients. Thus, they could be useful indicators in risk stratification of the disease, while we couldn’t find a reliable chemotherapeutic regimen which improved survival rates significantly. Therefore, this matter needs further investigation by clinicians.

Author Biography

Samer Akel, Tishreen University

Assistant Professor, Oncology department

Downloads

Published

2022-03-29

How to Cite

1.
عاقل س. Characteristics and survival rates of Acute Lymphoblastic Leukemia: A Retrospective cohort study. Tuj-hlth [Internet]. 2022Mar.29 [cited 2024Dec.26];44(1):11-24. Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/12014

Issue

Vol. 44 No. 1 (2022): Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.